Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356031 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Radiation Therapy for Sarcomas
A Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00356031 is a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00356031, a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation.
Conditions Studied
Interventions
- DRUG Bevacizumab
- RADIATION Radiation Therapy
- PROCEDURE Surgery
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356031
The ClinicalTrials.gov registry entry for NCT00356031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (75% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00356031 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00356031 about?
NCT00356031 is a clinical study titled "Bevacizumab and Radiation Therapy for Sarcomas". The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decrea...
What is the current status of trial NCT00356031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-07. Estimated completion is 2010-03.
What conditions does trial NCT00356031 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Fibrosarcoma.
What interventions are being tested in trial NCT00356031?
The interventions under investigation include: Bevacizumab (DRUG), Radiation Therapy (RADIATION), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00356031?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00356031 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.